CRBP vs VUZI Comparison

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices and third-party original design manufacturer (ODM) and original equipment manufacturer (OEM) devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.